$1.04 Billion is the total value of Sofinnova Investments, Inc.'s 164 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 57.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | Sell | Ascendis Pharma A/Sadr | $117,528,000 | +25.2% | 998,538 | -33.4% | 11.33% | -3.1% |
| AMRN | Amarinadr | $108,124,000 | +52.5% | 5,208,305 | 0.0% | 10.42% | +18.0% | |
| PRNB | Principia Biopharma | $69,299,000 | +24.1% | 2,038,208 | 0.0% | 6.68% | -4.0% | |
| NTRA | Natera | $63,934,000 | +47.7% | 3,100,560 | 0.0% | 6.16% | +14.3% | |
| OBSV | ObsEva SA | $60,748,000 | +1.0% | 4,749,623 | 0.0% | 5.86% | -21.8% | |
| YMAB | Y-mAbs Therapeutics, Inc | $55,153,000 | +28.9% | 2,104,278 | 0.0% | 5.32% | -0.3% | |
| ONCE | Spark Therapeutics | $54,807,000 | +191.0% | 481,270 | 0.0% | 5.28% | +125.1% | |
| Nucana Biomed Ltdordinary shares | $40,800,000 | +17.2% | 2,400,000 | 0.0% | 3.93% | -9.3% | ||
| CHRS | Coherus BioSciences | $39,123,000 | +50.7% | 2,868,221 | 0.0% | 3.77% | +16.6% | |
| NCNA | Nucana Biomed Ltdadr | $38,533,000 | +17.2% | 2,266,666 | 0.0% | 3.71% | -9.3% | |
| BOLD | Audentes Therapeutics | $36,431,000 | +83.0% | 933,640 | 0.0% | 3.51% | +41.6% | |
| MRUS | Merus N.V. | $28,965,000 | +5.5% | 1,961,039 | 0.0% | 2.79% | -18.4% | |
| New | Ishares Nasdaq Biotechnologyput | $27,055,000 | – | 242,000 | +100.0% | 2.61% | – | |
| KNSA | Kiniksa Pharmaceuticals, Ltd | $16,664,000 | -35.7% | 922,700 | 0.0% | 1.61% | -50.3% | |
| ITRM | Iterum Therapeutics | $13,677,000 | +58.1% | 1,726,514 | 0.0% | 1.32% | +22.3% | |
| AGN | New | Allergan plc | $12,981,000 | – | 88,665 | +100.0% | 1.25% | – |
| NVO | New | Novo Nordisk A/Sadr | $12,959,000 | – | 247,734 | +100.0% | 1.25% | – |
| ABBV | New | AbbVie Inccall | $12,089,000 | – | 150,000 | +100.0% | 1.16% | – |
| ACRS | Aclaris Therapeutics | $11,450,000 | -18.9% | 1,911,573 | 0.0% | 1.10% | -37.3% | |
| AZN | Sell | AstraZeneca PLCadr | $10,575,000 | -12.0% | 261,577 | -17.3% | 1.02% | -31.9% |
| ALNY | New | Alnylam Pharmaceuticals Inc | $9,964,000 | – | 106,616 | +100.0% | 0.96% | – |
| NBIX | Buy | Neurocrine Biosciences Inc | $9,904,000 | +125.4% | 112,406 | +82.8% | 0.96% | +74.6% |
| BIIB | New | Biogen Inccall | $9,455,000 | – | 40,000 | +100.0% | 0.91% | – |
| MGNX | Buy | MacroGenics Inc | $9,418,000 | +122.8% | 523,756 | +57.3% | 0.91% | +72.3% |
| CHMA | Chiasma | $8,477,000 | +67.2% | 1,630,221 | 0.0% | 0.82% | +29.3% | |
| ETTX | Entasis Therapeutics Holdings Inc. | $7,972,000 | +66.0% | 1,180,178 | 0.0% | 0.77% | +28.4% | |
| FOLD | Sell | Amicus Therapeutics Inc | $7,944,000 | +22.9% | 584,108 | -13.4% | 0.77% | -4.8% |
| ANAB | Buy | AnaptysBio Inc | $7,155,000 | +348.6% | 97,948 | +291.5% | 0.69% | +246.7% |
| DERM | Sell | Dermira Inc | $6,553,000 | +68.1% | 483,640 | -10.8% | 0.63% | +30.0% |
| XNCR | Buy | Xencor Inc | $6,519,000 | -9.7% | 209,907 | +5.1% | 0.63% | -30.2% |
| HALO | New | Halozyme Therapeutics Inc | $6,461,000 | – | 401,329 | +100.0% | 0.62% | – |
| BHVN | Buy | Biohaven Pharmaceutical Holding Company Ltd | $6,432,000 | +78.5% | 124,952 | +28.2% | 0.62% | +38.1% |
| Sell | MorphoSys AG | $6,313,000 | -23.2% | 69,344 | -13.9% | 0.61% | -40.6% | |
| BPMC | New | Blueprint Medicines Corp | $5,753,000 | – | 71,866 | +100.0% | 0.56% | – |
| HRTX | Sell | Heron Therapeutics Inc | $5,710,000 | -38.8% | 233,651 | -35.0% | 0.55% | -52.7% |
| SVRA | Buy | Savara Inc | $5,651,000 | -1.1% | 766,672 | +1.6% | 0.54% | -23.3% |
| RETA | Sell | Reata Pharmaceuticals Inc | $5,559,000 | -37.3% | 65,031 | -58.8% | 0.54% | -51.4% |
| ICPT | Sell | Intercept Pharmaceuticals Inc | $5,024,000 | -8.5% | 44,918 | -17.5% | 0.48% | -29.2% |
| DCPH | Sell | Deciphera Pharmaceuticals Inc | $4,981,000 | -10.6% | 214,604 | -19.2% | 0.48% | -30.8% |
| ORTX | Buy | Orchard Therapeutics PLCadr | $4,937,000 | +41.0% | 276,083 | +24.0% | 0.48% | +9.2% |
| INCY | Sell | Incyte Corp | $4,567,000 | -61.9% | 53,097 | -71.8% | 0.44% | -70.5% |
| KDMN | Buy | Kadmon Holdings Inc | $4,414,000 | +28.5% | 1,671,770 | +1.2% | 0.42% | -0.7% |
| SYBX | Synlogic Inc. | $4,364,000 | +8.3% | 574,972 | 0.0% | 0.42% | -16.1% | |
| AKBA | New | Akebia Therapeutics Inc | $4,232,000 | – | 516,761 | +100.0% | 0.41% | – |
| INSM | New | Insmed Inc | $4,072,000 | – | 140,057 | +100.0% | 0.39% | – |
| PBYI | New | Puma Biotechnology Inccall | $3,638,000 | – | 93,800 | +100.0% | 0.35% | – |
| FATE | Sell | Fate Therapeutics Inc | $3,581,000 | +21.5% | 203,742 | -11.3% | 0.34% | -6.0% |
| GWPH | Sell | GW Pharmaceuticals PLCadr | $3,371,000 | +15.4% | 20,000 | -33.3% | 0.32% | -10.7% |
| FGEN | Sell | FibroGen Inc | $3,207,000 | -13.4% | 59,017 | -26.2% | 0.31% | -33.0% |
| FOMX | Foamix Pharmaceuticals Ltd | $3,121,000 | +4.5% | 832,293 | 0.0% | 0.30% | -19.1% | |
| XBIT | New | XBiotech Inc | $2,881,000 | – | 261,391 | +100.0% | 0.28% | – |
| KALA | Sell | Kala Pharmaceuticals Inc | $2,856,000 | +31.1% | 345,346 | -22.5% | 0.28% | +1.5% |
| TGTX | New | TG Therapeutics Inc | $2,829,000 | – | 351,811 | +100.0% | 0.27% | – |
| New | FibroGen Incput | $2,718,000 | – | 50,000 | +100.0% | 0.26% | – | |
| OTIC | Otonomy Inc | $2,694,000 | +42.2% | 1,023,865 | 0.0% | 0.26% | +10.2% | |
| GLPG | New | Galapagos NVput | $2,355,000 | – | 20,000 | +100.0% | 0.23% | – |
| ARQL | New | ArQule Inc | $1,704,000 | – | 355,725 | +100.0% | 0.16% | – |
| CLVS | Sell | Clovis Oncology Inc | $1,654,000 | -68.0% | 66,635 | -76.8% | 0.16% | -75.3% |
| BMRN | Sell | Biomarin Pharmaceutical Inc | $1,643,000 | -86.3% | 18,494 | -86.8% | 0.16% | -89.4% |
| SNDX | Sell | Syndax Pharmaceuticals Inc | $1,121,000 | -28.0% | 213,359 | -39.1% | 0.11% | -44.3% |
| PDSB | New | PDS Biotechnology Corporation | $1,055,000 | – | 142,635 | +100.0% | 0.10% | – |
| PTLA | New | Portola Pharmaceuticals Inc | $1,041,000 | – | 30,000 | +100.0% | 0.10% | – |
| APLS | Apellis Pharmaceuticals, Inc | $967,000 | +47.9% | 49,580 | 0.0% | 0.09% | +14.8% | |
| OSMT | Osmotica Pharmaceuticals PLC | $911,000 | -53.5% | 253,089 | 0.0% | 0.09% | -63.9% | |
| ADVM | New | Adverum Biotechnologies Inc | $835,000 | – | 159,237 | +100.0% | 0.08% | – |
| IMGN | New | ImmunoGen Inccall | $406,000 | – | 150,000 | +100.0% | 0.04% | – |
| CNAT | New | Conatus Pharmaceuticals Inccall | $162,000 | – | 150,000 | +100.0% | 0.02% | – |
| PCRX | Exit | Pacira Pharmaceuticals Inc | $0 | – | -16,994 | -100.0% | -0.09% | – |
| EDGE | Exit | Edge Therapeutics | $0 | – | -2,852,711 | -100.0% | -0.11% | – |
| CNAT | Exit | Conatus Pharmaceuticals Inc | $0 | – | -638,197 | -100.0% | -0.14% | – |
| IMGN | Exit | ImmunoGen Inc | $0 | – | -447,075 | -100.0% | -0.27% | – |
| FPRX | Exit | Five Prime Therapeutics Inc | $0 | – | -315,344 | -100.0% | -0.36% | – |
| EPZM | Exit | Epizyme Inc | $0 | – | -563,655 | -100.0% | -0.43% | – |
| PBYI | Exit | Puma Biotechnology Inc | $0 | – | -190,627 | -100.0% | -0.48% | – |
| AIMT | Exit | Aimmune Therapeutics Inc | $0 | – | -175,775 | -100.0% | -0.52% | – |
| SRPT | Exit | Sarepta Therapeutics Inc | $0 | – | -48,894 | -100.0% | -0.66% | – |
| RIGL | Exit | Rigel Pharmaceuticals Inc | $0 | – | -3,382,174 | -100.0% | -0.97% | – |
| TSRO | Exit | TESARO Inc | $0 | – | -134,297 | -100.0% | -1.24% | – |
| GILD | Exit | Gilead Sciences Inc | $0 | – | -213,331 | -100.0% | -1.66% | – |
| SNY | Exit | Sanofi SAadr | $0 | – | -327,175 | -100.0% | -1.77% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.